Top gastroenterology stories: 6 common mistakes in treating ulcerative colitis, FDA approves Motegrity for constipation - Healio

The top story in gastroenterology this past week was a presentation from the Advances in Irritable Bowel Disease meeting which revealed six common mistakes to avoid when treating patients with ulcerative colitis.

Other popular stories included the FDA approval of Motegrity for chronic idiopathic constipation, a video from the Advances in IBD meeting detailing how post-marketing safety data of Entyvio for Crohn’s disease and ulcerative colitis was consistent with previous clinical trials, research demonstrating that differences in gut microbiota could help diagnose IBD and irritable bowel syndrome and a Healio exclusive on how protocols are needed to overcome “diffusion of responsibility” and maximize Lynch syndrome testing. – by Alaina Tedesco

6 common mistakes when treating patients with ulcerative colitis

ORLANDO — When a patient with ulcerative colitis is sick enough to be admitted to the hospital, the stakes can be incredibly high. In a presentation at Advances in IBD 2018, Corey Siegel, MD, of the Dartmouth-Hitchcock Medical Center, said there is little room for mistakes with these patients. Read more.

FDA approves Motegrity for chronic idiopathic constipation

The FDA has approved Motegrity for the treatment of adults with chronic idiopathic constipation, according to a company press release. Read more.

VIDEO: Entyvio post-marketing safety data consistent with previous clinical trials

ORLANDO — Four-year post-marketing data appeared to demonstrate a favorable safety profile of Entyvio in patients with Crohn’s disease and ulcerative colitis that was consistent with what had been established in previous clinical trials, according to study results presented at Advances in IBD 2018. Read more.

Differences in gut microbiota could help diagnose IBD, IBS

Changes in a patient’s gut microbiota could help clinicians differentiate patients with inflammatory bowel disease and those with irritable bowel syndrome, according to research published in Science Translational Medicine. Read more.

Q&A: Protocols needed to overcome ‘diffusion of responsibility,’ maximize Lynch syndrome testing

Researchers have identified inconsistent beliefs among medical specialists as to who is responsible for ordering tumor microsatellite instability and immunohistochemistry tests for Lynch syndrome. Read more.

http://bit.ly/2QVlhy3